Showing results (2081-2090 of 5,535) with videos related to
Sort By:
Pageof 554
Inflammatory Bowel Diseases|August 27, 2016
A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big BusinessChristina Y Ha, Asher KornbluthInflammatory Bowel Diseases|March 12, 2010
N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel diseaseKan Uchiyama, Makoto Nakamura, Shunichi Odahara, et al.Inflammatory Bowel Diseases|March 3, 2010
Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximabZhe Li, Ingrid Arijs, Gert De Hertogh, et al.Inflammatory Bowel Diseases|January 6, 2010
CD95 is cytoprotective for intestinal epithelial cells in colitisSun-Mi Park, Lina Chen, Manling Zhang, et al.Inflammatory Bowel Diseases|January 6, 2010
Surgical management of pyogenic complications of Crohn's diseaseChristina Cellini, Bashar Safar, James FleshmanInflammatory Bowel Diseases|December 23, 2009
Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's diseaseAndrew Ippoliti, Shane Devlin, Ling Mei, et al.Inflammatory Bowel Diseases|October 22, 2005
Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulationFrank Hoentjen, Gjalt W Welling, Hermie J M Harmsen, et al.Inflammatory Bowel Diseases|October 22, 2005
Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's diseaseStéphane Nancey, Elodie Blanvillain, Béatrice Parmentier, et al.Inflammatory Bowel Diseases|October 29, 2005
Understanding the drug development processPatricia R Robuck, John I WurzelmannInflammatory Bowel Diseases|October 29, 2005
Design issues and outcomes in IBD clinical trialsBruce E Sands, Maria T Abreu, George D Ferry, et al.Pageof 554